Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Diabetologia

• Publication date

  1993-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/BF00400356PMID 8104834
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The hypertriglyceridemias: Risk and management. Epidemiology.

  1991cited by this paper
• Plasma triglyceride and coronary heart disease.

  1991cited by this paper
• Hypofibrinolysis and insulin-resistance.

  1991cited by this paper
• Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis

  1991cited by this paper
• The hypertriglyceridemias: risk and management. Introduction.

  1991cited by this paper
• Impaired fibrinolysis and risk of thromboembolism.

  1991cited by this paper
• Alcohol and Fibrinolysis

  1990cited by this paper
• Plasminogen activator inhibitor I response to a carbohydrate meal in obese subjects

  1990cited by this paper
• Regular moderate wine consumption for five weeks increases plasma activity of the plasminogen activator inhibitor-1 (PAI-1) in healthy young volunteers

  1990cited by this paper
• Elevated fibrinogen and plasminogen activator inhibitor (PAI‐1) in hypertension are related to metabolic risk factors for cardiovascular disease

  1990cited by this paper
• Dietary regulation of fibrinolytic factors.

  1990cited by this paper
• Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1.

  1990cited by this paper
• Hypertriglyceridaemia, triglyceride-rich lipoproteins and coronary heart disease.

  1990cited by this paper
• 9 Hypertriglyceridaemia, triglyceride-rich lipoproteins and coronary heart disease

  1990cited by this paper
• Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein.

  1990cited by this paper
• "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes.

  1990cited by this paper
• The Fibrinolytic Enzyme System and Its Role in the Etiology of Thromboembolic Disease

  1990cited by this paper
• Body composition and weight reduction in relation to antigen and activity of plasminogen activitor inhibitor (PAI-1) in overweight individuals

  1990cited by this paper
• The relationships of concentrations of insulin, intact proinsulin and 32–33 split proinsulin with cardiovascular risk factors in Type 2 (non-insulin-dependent) diabetic subjects

  1990cited by this paper
• Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects.

  1990cited by this paper
• Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a north Swedish population.

  1989cited by this paper
• Fibrinolytic capacity following stimulation with desmopressin acetate in patients with diabetes mellitus.

  1989cited by this paper
• Increased Plasminogen Activator Inhibitor Activity in Non Insulin Dependent Diabetic Patients – Relationship with Plasma Insulin

  1989cited by this paper
• Reduction of Elevated Plasminogen Activator Inhibitor Levels During Modest Weight Loss

  1989cited by this paper
• Plasma Plasminogen Activator Inhibitor‐1 in Angina Pectoris: Influence of Plasma Insulin and Acute‐phase Response

  1989cited by this paper
• Insulin deficiency in non-insulin-dependent diabetes.

  1989cited by this paper
• Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: a cross-sectional study in Norsjö, Sweden.

  1989cited by this paper
• Insulin Stimulates the Synthesis of Plasminogen Activator Inhibitor 1 by the Human Hepatocellular Cell Line Hep G2

  1988cited by this paper
• Hyperinsulinemia Is Characterized by Jointly Disturbed Plasma VLDL, LDL, and HDL Levels: A Population‐Based Study

  1988cited by this paper
• Tissue‐Type Plasminogen Activator Antigen and Plasminogen Activator Inhibitor in Diabetes Mellitus

  1988cited by this paper
• Banting lecture 1988. Role of insulin resistance in human disease.

  1988cited by this paper
• The effect of body build, diet and endocrine factors on the extrinsic fibrinolytic system in healthy young women.

  1988cited by this paper
• Impaired fibrinolysis in coronary artery disease.

  1988cited by this paper
• Treatment of deep vein thrombosis with a very low molecular weight heparin (CY 222 - Choay): Thrombolysis and plasma fibrinolytic parameters

  1988cited by this paper
• Role of Insulin Resistance in Human Disease

  1988cited by this paper
• CLINICAL RELEVANCE OF HIGH PAI-1 LEVEL IN PATIENTS WITH IDIOPATHIC/RECURRENT DEEP VENOUS THROMBOSIS

  1988cited by this paper
• Deficient t-PA Release and Elevated PA Inhibitor Levels in Patients with Spontaneous or Recurrent Deep Venous Thrombosis

  1987cited by this paper
• Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1.

  1987cited by this paper
• Metformin Decreases the High Plasminogen Activator Inhibition Capacity, Plasma Insulin and Triglyceride Levels in Non-Diabetic Obese Subjects

  1987cited by this paper
• Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

  1987cited by this paper
• Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations.

  1987cited by this paper
• The extrinsic fibrinolytic system in survivors of myocardial infarction.

  1987cited by this paper
• MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test.

  1986cited by this paper
• Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects.

  1986cited by this paper
• Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.

  1985cited by this paper
• Diabetes mellitus. Report of a WHO Study Group.

  1985cited by this paper
• Evidence for a rapid inhibitor to tissue plasminogen activator in plasma.

  1983cited by this paper
• Fish eye disease: a new familial condition with massive corneal opacities and dyslipoproteinaemia Clinical and laboratory studies in two afflicted families

  1982cited by this paper
• Fish-eye disease. A new familial condition with massive corneal opacities and dyslipoproteinaemia.

  1979cited by this paper
• Low vascular fibrinolytic activity in obesity.

  1975cited by this paper
• Fibrinolysis and body build

  1968cited by this paper
• Fibrinolysis and body bulid. Interrelationships between blood fibrinolysis, body composition and parameters of lipid and carbohydrate metabolism.

  1968cited by this paper
• FIBRINOLYSIS IN OBESITY.

  1964cited by this paper
• Relationship between blood fibrinoytic activity and body fatness.

  1963cited by this paper
• Food Composition Tables.

  1944cited by this paper

• Dietary Fats and the Gut Microbiota: Their impacts on lipid-induced metabolic syndrome

  2022cites this paper
• Bioactive lipids in metabolic syndromes and hemostatic factors and fibrinolysis

  2021cites this paper
• Gender difference in plasminogen activator inhibitor-1 activity in patients with type 2 diabetes with and without albuminuria, a matched case-control study

  2019cites this paper
• Effect of Lipid-lowering Therapy and Regular Exercise on the Fibrinolytic System in Patients with Metabolic Syndrome

  2019cites this paper
• Functional Features of Vascular Endothelium with Developing Arterial Hypertension

  2019cites this paper
• Adipose Gene Expression Profile Changes With Lung Allograft Reperfusion

  2017cites this paper
• Plasminogen Activator Inhibitor-1 Predicts Quantity of Hepatic Steatosis Independent of Insulin Resistance and Body Weight

  2016cites this paper
• Diabetic and dyslipidaemic morbidly obese exhibit more liver alterations compared with healthy morbidly obese

  2016cites this paper
• The association between fibrinolysis markers and body composition in black adults in the North West Province of South Africa

  2014cites this paper
• Serum Level of Plasminogen Activator Inhibitor Type-1 in Addicted Patients with Coronary Artery Disease

  2014cites this paper
• Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment

  2014cites this paper
• Correlates and reference limits of plasma gamma-glutamyltransferase fractions from the Framingham Heart Study.

  2013cites this paper
• Psychiatric remission with warfarin: Should psychosis be addressed as plasminogen activator imbalance?

  2013cites this paper
• Physiological, pathological and potential therapeutic roles of adipokines.

  2012cites this paper
• Inhibition of adipocyte differentiation in 3T3-L1 cell line by quercetin or isorhamnetin

  2012cites this paper
• Sphingosine 1-Phosphate Distribution in Human Plasma: Associations with Lipid Profiles

  2012cites this paper
• Type 2 Diabetes and Fibrinolysis

  2011cites this paper
• patients The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic

  2011cites this paper
• Adipose Tissue and Blood Pressure Regulation

  2010cites this paper
• Residual risk reduction initiative: Výzva ke sníž ení reziduálního vaskulárního rizika u pacientů s dyslipidemií

  2010cites this paper
• Portal Job strain and risk indicators for cardiovascular disease in young female nurses

  2010cites this paper
• Triglyceride concentration and waist circumference influence alcohol-related plasminogen activator inhibitor-1 activity increase in black South Africans

  2010cites this paper
• Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

  2010cites this paper
• Relationship between resistin and aPAI‐1 levels with insulin resistance in Saudi children

  2010cites this paper
• Non-LDL-related dyslipidaemia and coronary risk: a case-control study

  2010cites this paper
• Studies on lipoprotein metabolism and atherogenesis

  2009cites this paper
• Plasminogen activator inhibitor-1 is associated with coronary artery calcium in Type 1 diabetes.

  2009cites this paper
• The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients

  2008cites this paper
• PAI-1 gene 4G/5G polymorphism, cytokine levels and their relations with metabolic parameters in obese children

  2008cites this paper
• The Effect of Plasminogen Activator Inhibitor-1 −675 4G/5G Polymorphism on PAI-1 Gene Expression and Adipocyte Differentiation

  2008cites this paper
• Diabetes mellitus as a prothrombotic condition

  2007cites this paper
• Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis

  2007cites this paper
• Microvascular tissue plasminogen activator is reduced in diabetic neuropathy

  2007cites this paper
• Hyperinsulinemia, Hyperglycemia, and Impaired Hemostasis

  2007cites this paper
• Tissue Distribution and Regulation of Plasminogen Activator Inhibitor-I in Obese Mice'

  2007cites this paper
• Plasminogen activator inhibitor-1 modulates adipocyte differentiation.

  2006cites this paper
• Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome.

  2006cites this paper
• Nicotinic acid: the broad‐spectrum lipid drug. A 50th anniversary review

  2005cites this paper
• Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome.

  2005cites this paper
• Type 2 diabetes: an atherothrombotic syndrome.

  2005cites this paper
• Hemostatic risk factors and insulin sensitivity, regional body fat distribution, and the metabolic syndrome.

  2005cites this paper
• Lipids, thrombosis and cardiovascular disease in diabetes

  2005cites this paper
• Postprandial activation of hemostatic factors: role of dietary fatty acids.

  2005cites this paper
• The Metabolic Syndrome and Inflammation

  2004cites this paper
• Postprandial variations in fibrinolytic activity in middle-aged men are modulated by plasminogen activator inhibitor I 4G-675/5G genotype but not by the fat content of a meal.

  2004cites this paper
• Key References: Basic Fibrinolysis and Thrombolysis Selected References: 1987–1997

  2004cites this paper
• Interrelationships between the fibrinolytic system and lipoproteins in the pathogenesis of coronary atherosclerosis.

  2004cites this paper
• Cholesterol diet enhances daily rhythm of Pai-1 mRNA in the mouse liver.

  2004influential citation
• The Emerging Role of Lipoproteins in Atherogenesis: Beyond LDL Cholesterol

  2004cites this paper
• Promoter (4G/5G) Plasminogen Activator Inhibitor-1 Genotype and Plasminogen Activator Inhibitor-1 Levels in Blacks, Hispanics, and Non-Hispanic Whites: The Insulin Resistance Atherosclerosis Study

  2003cites this paper
• Increased plasma levels of plasminogen activator inhibitor-1 and soluble vascular cell adhesion molecule after triacylglycerol infusion in man

  2003cites this paper
• Profilaktyka i leczenie trombofilii cukrzycowej w świetle najnowszych badań

  2003cites this paper
• Insulin resistance but not visceral adipose tissue is associated with plasminogen activator inhibitor type 1 levels in overweight and obese premenopausal African-American women

  2003cites this paper
• Exercise-Induced Changes in Coagulation and Fibrinolysis in Healthy Populations and Patients with Cardiovascular Disease

  2003cites this paper
• Blood coagulation and fibrinolysis before and after exhaustive exercise in patients with IDDM

  2003cites this paper
• The renin-angiotensin system is involved in the production of plasminogen activator inhibitor type 1 by cultured endothelial cells in response to chylomicron remnants.

  2003cites this paper
• Pathogenesis and treatment of lipodystrophy in hiv-infected patients receiving highly active antiretroviral therapy

  2003cites this paper
• Regulation of Plasma PAI-1 Concentrations in HAART-Associated Lipodystrophy During Rosiglitazone Therapy

  2003cites this paper
• Insulin resistance: an atherothrombotic syndrome

  2003cites this paper
• Plasma PAI-1 Levels Are More Strongly Related to Liver Steatosis Than to Adipose Tissue Accumulation

  2003cites this paper
• Plasminogen Activator Inhibitor‐1: Physiologic Role, Regulation, and the Influence of Common Pharmacologic Agents

  2002cites this paper
• Effect of surgical castration on risk factors for arteriosclerosis of patients with prostate cancer.

  2002cites this paper
• Elevated plasma activator inhibitor 1 is not related to insulin resistance and to gene polymorphism in healthy centenarians.

  2002cites this paper
• ...OM MAN INTE SJÄLV

  2002cites this paper
• Angiotensin and vascular fibrinolytic balance.

  2002cites this paper
• Bezafibrate attenuates the overexpression of plasminogen activator inhibitor-1 messenger RNA by a combination of mono-unsaturated fatty acid and insulin in hepG2 cells.

  2001cites this paper
• Postprandial triglycerides and blood coagulation.

  2001cites this paper
• Disruption of the plasminogen activator inhibitor‐1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice

  2001cites this paper
• Plasminogen Activator Inhibitor Type-1 (Part One): Basic Mechanisms, Regulation, and Role for Thromboembolic Disease

  2001cites this paper
• [Postprandial hyperlipidemia, small and dense LDL, HDL sub-fractions].

  2001cites this paper
• Increased plasma fibrinolysis and tissue-type plasminogen activator/tissue-type plasminogen activator inhibitor ratios after ethanol withdrawal in chronic alcoholics

  2001cites this paper
• Accumulation of Triglyceride-Rich Lipoprotein in Subjects With Abdominal Obesity: The Biguanides and the Prevention of the Risk of Obesity (BIGPRO) 1 Study

  2001cites this paper
• Distribution and cardiovascular risk correlates of serum triglycerides in young adults from a biracial community: the Bogalusa Heart Study.

  2001cites this paper
• Similar PAI-1 expression in visceral and subcutaneous fat of postmenopausal women.

  2001cites this paper
• HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study.

  2000cites this paper
• Job strain and risk indicators for cardiovascular disease in young female nurses.

  2000cites this paper
• Relationship between fibrinolytic and metabolic variables: a study in patients attending a lipid clinic

  2000cites this paper
• Growth Hormone and Syndrome X

  2000cites this paper
• Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism?

  2000cites this paper
• Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study.

  2000cites this paper
• Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance

  2000cites this paper
• Improved fibrinolysis by intense lifestyle intervention. A randomized trial in subjects with impaired glucose tolerance

  1999cites this paper
• Lack of evidence for secretion of plasminogen activator inhibitor-1 by human subcutaneous adipose tissue in vivo.

  1999cites this paper
• Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study.

  1999cites this paper
• Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity.

  1999cites this paper
• Hypertriglyceridemia, insulin resistance, and the metabolic syndrome.

  1999cites this paper
• Studies in hypertriglyceridaemia VI: serum lathosterol concentration is raised in hypertriglyceridaemic non‐diabetic males with hyperinsulinaemia

  1999cites this paper
• Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction.

  1999cites this paper
• Lipoproteins and the haemostatic system in atherothrombotic disorders.

  1999cites this paper
• Insulin sensitivity and haemostatic factors in men at high and low cardiovascular risk. The Risk Factor Intervention Study Group.

  1999cites this paper
• Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS).

  1999cites this paper
• PAI-1, Obesity, and Insulin Resistance

  1999cites this paper
• 冠動脈疾患における動脈硬化性レムナントとしての中間比重リポ蛋白(IDL)とアポ蛋白B48の関与について

  1999cites this paper
• Tissue factor gene expression in the adipose tissues of obese mice.

  1998cites this paper
• Increased PAI activity and PAI-1 antigen occurring with an oral fat load: associations with PAI-1 genotype and plasma active TGF-beta levels.

  1998cites this paper
• Atherosclerosis prevention for the next decade: risk assessment beyond low density lipoprotein cholesterol.

  1998cites this paper
• Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort.

  1998cites this paper
• Intense nonpharmacological intervention in subjects with multiple cardiovascular risk factors: decreased fasting insulin levels but only a minor effect on plasma plasminogen activator inhibitor activity.

  1998cites this paper
• Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells.

  1998cites this paper
• Diabetes is a Vascular Disease

  1998cites this paper